Results 91 to 100 of about 55,457 (267)

Co-Treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer and current treatments exert small effects on life expectancy. The most common adjuvant treatment for PDAC is gemcitabine.
Sette, Claudio, Terracciano F., Fave G. D., Panzeri V., Sette C., Passacantilli I., Capurso G.   +6 more
core   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice

Journal of Cancer Research and Therapeutics, 2018
Pancreatic cancer in a common tumor in our country for which there are various treatment alternatives.Evaluate the effectiveness and safety of nab-paclitaxel and gemcitabine in everyday clinical practice.Observational, retrospective study at a tertiary university hospital.We included patients diagnosed of metastatic or locally advanced pancreatic ...
Cristina, Casanova-Martinez, Elena Yaiza, Romero-Ventosa, Sonia, González-Costas, Cecilia, Arroyo-Conde, Guadalupe, Piñeiro-Corrales   +4 more
openaire   +2 more sources

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

, 2014
Si Sun,1 Lichen Tang,2 Jian Zhang,1 Fangfang Lv,1 Zhonghua Wang,1 Leiping Wang,1 Qunling Zhang,1 Chunlei Zheng,1 Lixin Qiu,1 Zhen Jia,1 Yunhua Lu,1 Guangyu Liu,2 Zhimin Shao,2 Biyun Wang,1 Xichun Hu1 1Department of Medical Oncology, Fudan University ...
Zhang J, Wang B, Lu Y, Hu X, Zhang Q, Wang L, Qiu L, Tang L, Lv F, Shao Z, Sun S, Zheng C, Wang Z, Jia Z, Liu G   +14 more
core  

Токсичность и эффективность комбинации гемцитабина и nab-паклитаксела (паклитаксел + альбумин) в Российской популяции больных раком поджелудочной железы: результаты многоцентрового ретроспективного исследования

, 2019
Introduction. The results of randomized MPACT study have demonstrated that the addition of nab-paclitaxel to gemcitabine leads to a statistically significant increase in life expectancy.
A. A. Tryakin, В. А. Чубенко, А. И. Хасанова, О. V. Romanchuk, Д. А. Носов, Н. В. Иванова, I. Yu. Stradaeva, I. A. Pokataev, V. A. Chubenko, D. Yu. Yukalchuk, Ф. В. Моисеенко, О. И. Кит, А. С. Переплетова, А. Ю. Горяинова, Х. С. Мусаева, D. A. Nosov, А. В. Андросова, О. В. Хаваева, N. V. Karpova, V. Е. Shikina, М. А. Лядова, М. Л. Степанова, Kh. S. Musaeva, А. А. Трякин, В. М. Филиппова, М. L. Stepanova, N. L. Buzova, D. М. Ponomarenko, A. V. Androsova, Л. А. Загорская, А. D. Kruglov, М. Ю. Федянин, N. V. Ivanova, S. А. Tyulyandin, Н. В. Карпова, О. I. Kit, А. S. Perepletova, Д. Ю. Юкальчук, Л. Ю. Владимирова, С. А. Тюляндин, М. Yu. Fedyanin, V. М. Filippova, А. Yu. Goryainova, Н. Л. Бузова, О. V. Khavaeva, И. Ю. Страдаева, О. В. Романчук, А. Д. Круглов, И. Л. Попова, A. V. Belonogov, F. V. Moiseenko, В. Е. Шикина, M. A. Lyadova, А. В. Белоногов, И. Ш. Теспижек, I. Sh. Tespizhek, А. I. Khasanova, И. А. Покатаев, L. A. Zagorskaya, Д. М. Пономаренко, L. Yu. Vladimirova, I. L. Popova   +61 more
core   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion

BMC Cancer
Background Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential
Carlos Sergio Rocha Silva, Lisete Ribeiro Teixeira, Karina Rocha Pereira, Philippe Figueiredo Braga Colares, Vanessa Adelia Alvarenga, Roberta Karla Barbosa Sales, Amanda Cabral Roque, Evaldo Marchi, Ronei Luciano Mamoni, Milena Marques Pagliarelli Acencio   +9 more
doaj   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

Interdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione, Ana Talamillo, Juan M. Falcón‐Pérez   +2 more
wiley   +1 more source

Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives To evaluate the prognostic significance of baseline and longitudinal changes in prognostic nutritional index (PNI) in localized pancreatic ductal adenocarcinoma (PDAC) and to assess the complementary prognostic value of PNI with tumor burden measured by circulating tumor DNA (ctDNA).
Alex Horowitz, Claire Shen, Dominic J. Vitello, Madison Cox, Amy Wells, Krishay Sridalla, David J. Bentrem, Qiang Zhang, Ishan Roy, Akhil Chawla   +9 more
wiley   +1 more source